MX2017009505A - Derivados de 9h-pirrolo-dipiridina. - Google Patents

Derivados de 9h-pirrolo-dipiridina.

Info

Publication number
MX2017009505A
MX2017009505A MX2017009505A MX2017009505A MX2017009505A MX 2017009505 A MX2017009505 A MX 2017009505A MX 2017009505 A MX2017009505 A MX 2017009505A MX 2017009505 A MX2017009505 A MX 2017009505A MX 2017009505 A MX2017009505 A MX 2017009505A
Authority
MX
Mexico
Prior art keywords
pyrrolo
dipyridine
derivatives
dipyridine derivatives
radiopharmaceuticals
Prior art date
Application number
MX2017009505A
Other languages
English (en)
Inventor
Anil Sabnis Yogesh
Mercier Joël
Provins Laurent
Vermeiren Céline
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of MX2017009505A publication Critical patent/MX2017009505A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0463—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La invención se refiere a derivados de 9H-pirrolo-dipiridina de la fórmula I, procesos para prepararlos, composiciones farmacéuticas que los contienen y su uso como radiofármacos en particular como agentes de formación de imágenes para la detección de agregados Tau.
MX2017009505A 2015-02-02 2016-01-29 Derivados de 9h-pirrolo-dipiridina. MX2017009505A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15153448 2015-02-02
PCT/EP2016/051993 WO2016124508A1 (en) 2015-02-02 2016-01-29 9h-pyrrolo-dipyridine derivatives

Publications (1)

Publication Number Publication Date
MX2017009505A true MX2017009505A (es) 2017-11-02

Family

ID=52477553

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017009505A MX2017009505A (es) 2015-02-02 2016-01-29 Derivados de 9h-pirrolo-dipiridina.

Country Status (17)

Country Link
US (3) US20180022748A1 (es)
EP (1) EP3253762B1 (es)
JP (1) JP6579670B2 (es)
KR (1) KR102621513B1 (es)
CN (1) CN107207508B (es)
AU (1) AU2016214537B2 (es)
BR (1) BR112017016311A2 (es)
CA (1) CA2973648C (es)
CL (1) CL2017001923A1 (es)
DK (1) DK3253762T3 (es)
EA (1) EA036518B1 (es)
ES (1) ES2875734T3 (es)
IL (1) IL253381B (es)
MX (1) MX2017009505A (es)
MY (1) MY191590A (es)
SG (1) SG11201705727TA (es)
WO (1) WO2016124508A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2247558T3 (da) 2008-02-14 2022-02-21 Lilly Co Eli Nye billeddannelsesmidler til detektering af neurologisk dysfunktion
AU2016214537B2 (en) * 2015-02-02 2018-05-10 Ucb Biopharma Sprl 9H-pyrrolo-dipyridine derivatives
JP7059270B2 (ja) * 2016-07-22 2022-04-25 エーシー・イミューン・エス・アー タウタンパク質凝集体を画像化するための化合物
CA3030511A1 (en) * 2016-07-22 2018-01-25 Ac Immune S.A. Compounds for imaging tau protein aggregates
SG11201901983PA (en) * 2016-09-09 2019-04-29 Hoffmann La Roche Process for preparation of 2-(6-nitropyridin-3-yl)-9h-dipyrido[2,3-b;3',4'-d]pyrrole
KR102570992B1 (ko) * 2016-11-01 2023-08-28 아비나스 오퍼레이션스, 인코포레이티드 타우(Tau)-단백질 표적화 프로탁(PROTAC) 및 관련 사용 방법
JP7370859B2 (ja) * 2017-06-02 2023-10-30 富士フイルム富山化学株式会社 タウオパチー予防または治療剤
SG11201911515QA (en) 2017-06-02 2020-01-30 Fujifilm Toyama Chemical Co Ltd Agent for preventing or treating spinocerebellar ataxia
AU2018276638B2 (en) 2017-06-02 2021-04-08 Fujifilm Toyama Chemical Co., Ltd. Agent for preventing or treating brain atrophy
WO2018221728A1 (ja) 2017-06-02 2018-12-06 富山化学工業株式会社 アルツハイマー型認知症予防または治療剤
US11666551B2 (en) 2017-06-02 2023-06-06 Fujifilm Toyama Chemical Co., Ltd. Agent for reducing amount of amyloid β protein
EP3705121B1 (en) 2017-10-30 2023-08-30 FUJIFILM Toyama Chemical Co., Ltd. Emopamil binding protein binding agent and use thereof
WO2019145294A1 (en) * 2018-01-24 2019-08-01 Ac Immune Sa Novel method of preparing an imaging compound
EP3743423A1 (en) 2018-01-24 2020-12-02 AC Immune SA Gamma-carboline compounds for the detection of tau aggregates
EP3743426A1 (en) * 2018-01-24 2020-12-02 AC Immune SA Azacarboline compounds for the detection of tau aggregates
CN114867727A (zh) 2019-07-17 2022-08-05 阿尔维纳斯运营股份有限公司 Tau蛋白靶向化合物及相关使用方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1268771A (en) 1968-03-15 1972-03-29 Glaxo Lab Ltd Azacarbazoles
WO2008132454A1 (en) * 2007-04-26 2008-11-06 Ge Healthcare Limited Carbolines and their use as imaging agents
DK2247558T3 (da) * 2008-02-14 2022-02-21 Lilly Co Eli Nye billeddannelsesmidler til detektering af neurologisk dysfunktion
JP5557849B2 (ja) * 2008-12-19 2014-07-23 ブリストル−マイヤーズ スクイブ カンパニー カルバゾールおよびカルボリンキナーゼ阻害剤
EP2852572B1 (en) * 2012-05-22 2020-04-01 Eli Lilly and Company Carboline and carbazole based imaging agents for detecting neurological dysfunction
WO2014194169A1 (en) 2013-05-31 2014-12-04 The General Hospital Corporation Radiosynthesis of tau radiopharmaceuticals
US9774356B2 (en) * 2013-07-24 2017-09-26 Telefonaktiebolaget Lm Ericsson (Publ) Method and apparatus relating to reception of radio signals
SG11201602786UA (en) * 2013-10-08 2016-05-30 Hoffmann La Roche Diazacarbazole derivatives as tau-pet-ligands
WO2015110263A1 (en) * 2014-01-21 2015-07-30 Ac Immune Sa Carbazole and carboline compounds for use in the diagnosis, treatment, alleviation or prevention of disorders associated with amyloid or amyolid-like proteins
AU2016214537B2 (en) * 2015-02-02 2018-05-10 Ucb Biopharma Sprl 9H-pyrrolo-dipyridine derivatives

Also Published As

Publication number Publication date
EP3253762A1 (en) 2017-12-13
DK3253762T3 (da) 2021-07-19
WO2016124508A1 (en) 2016-08-11
KR20170113607A (ko) 2017-10-12
CL2017001923A1 (es) 2018-02-16
CN107207508B (zh) 2020-02-28
MY191590A (en) 2022-06-30
IL253381A0 (en) 2017-09-28
US20210047326A1 (en) 2021-02-18
EA036518B1 (ru) 2020-11-18
ES2875734T3 (es) 2021-11-11
BR112017016311A2 (pt) 2018-03-27
CA2973648A1 (en) 2016-08-11
US20180022748A1 (en) 2018-01-25
EA201791733A1 (ru) 2018-01-31
US20220213103A1 (en) 2022-07-07
JP2018503673A (ja) 2018-02-08
AU2016214537B2 (en) 2018-05-10
IL253381B (en) 2020-10-29
JP6579670B2 (ja) 2019-09-25
US11312716B2 (en) 2022-04-26
EP3253762B1 (en) 2021-05-05
CN107207508A (zh) 2017-09-26
US12006316B2 (en) 2024-06-11
SG11201705727TA (en) 2017-08-30
CA2973648C (en) 2023-09-26
AU2016214537A1 (en) 2017-08-03
KR102621513B1 (ko) 2024-01-04

Similar Documents

Publication Publication Date Title
MY191590A (en) 9h-pyrrolo-dipyridine derivatives
PH12017501413A1 (en) Substituted nucleoside derivatives useful as anticancer agents
PH12017500408B1 (en) Heteroaryl compounds as btk inhibitors and uses thereof
HK1243999A1 (zh) 新型3-吲哚取代的衍生物、藥物組合物及使用方法
MX2016014615A (es) Compuestos heterociclicos deuterados y su uso como agentes formadores de imagenes.
PH12016501791A1 (en) Muscarinic receptor agonists
PH12015501609A1 (en) Phenicol antibacterials
PH12017501539A1 (en) Disacetoxytubulysin h and analogs thereof
TW201613864A (en) Novel compounds
PH12017501280A1 (en) Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators
PH12016501686A1 (en) Pharmaceutical compositions of sitagliptin
MX2017007377A (es) Compuestos organicos.
PH12017500348B1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
TR201900659T4 (tr) Mineralokortikoid reseptör modülatörleri olarak benzoksazinon amidleri.
PH12015502632A1 (en) Cxcr7 receptor modulators
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
IN2014CH00840A (es)
MX2016003725A (es) Compuestos y su uso para la preparacion de agentes de formacion de imagen tau y formulaciones para la formacion de imagen tau.
IN2015DN02109A (es)
MX371158B (es) Compuestos inhibidores de pde2.
MX360040B (es) Nuevo agente antibacteriano derivado de florfenicol unido a sulfoximina y el uso del mismo en el tratamiento de infecciones bacterianas en ganado vacuno.
MX2016015468A (es) Composiciones farmaceuticas que contienen montelukast y levocetirizina.
PL406972A1 (pl) Sposób otrzymywania kompozycji zawierającej klotrimazol oraz kompozycja farmaceutyczna uzyskana tym sposobem